Patents Assigned to L'Institut Pasteur
  • Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-&kgr;B) activation
    Patent number: 6824972
    Abstract: Incontinentia Pigmenti (IP) is a neurocutaneous genodermatosis that segregates as an X-linked dominant disorder with a high probability of prenatal male lethality. A locus in Xq28 containing NF-&kgr;B Essential Modulator, a gene product involved in the activation of NF-kB and central to many pro-inflammatory and apoptotic pathways, contains mutations in the majority of cases of IP. Disclosed are methods, compositions and kits directed to a defect in a NF-&kgr;B related disease such as IP.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: November 30, 2004
    Assignees: Baylor College of Medicine, Cambridge University Technical Services Limited, Consiglio Nazionale Delle Richerche, INSERM, L'Institut Pasteur
    Inventors: Sue J. Kenwrick, Hayley Woffendin, Arnold Munnich, Asmae Smahi, Alain Israel, Annemarie Poustka, Nina Heiss, Michele D'Urso, Richard A. Lewis, David L. Nelson, Swaroop Aradhya, Moise Levy